The Joint Corp. (JYNT) AI Stock Analysis

The Joint Corp. operates within the chiropractic healthcare sector, specializing in the development, ownership, operation, support, and management of chiropractic clinics throughout the United States. Its operations are organized into two segments: Corporate Clinics and Franchise Operations. The company expands its clinical footprint using direct ownership, management arrangements, franchising agreements, and regional developers. As of March 1, 2022, The Joint Corp. managed approximately 700 clinic locations nationwide. Headquartered in Scottsdale, Arizona, the business aims to provide accessible and standardized chiropractic healthcare services through its combined network of company-owned clinics and franchise partners.

Revenue peaked at $101.3M in FY2022 before dropping 53.6% to $47.0M in FY2023. Revenue subsequently grew 11.0% to $52.2M in FY2024 and 5.2% to $54.9M in FY2025, resulting in a 5-year revenue CAGR of -1.3%. Operating margin decreased from 7.7% in FY2021 to -3.6% in FY2024 and -1.6% in FY2025. After net losses of -$9.8M in FY2023 and -$5.8M in FY2024, net income rebounded to $2.9M in FY2025. Over the trailing twelve months, revenue reached $58.5M with a profit margin of 6.5% and an operating margin of 3.2%. In the latest quarter ended June 30, 2026, quarterly revenue grew 14.4% year-over-year, while quarterly earnings grew 652.6%.

As of June 30, 2026, The Joint Corp. held $22.2M in cash and short-term investments against $2.0M in total debt, yielding net cash of $20.1M. Total assets stood at $51.6M against shareholders' equity of $15.9M. The company shows a current ratio of 1.83 and a debt-to-equity ratio of 0.13. For FY2025, operating cash flow was $1.8M and free cash flow was $334,724. Capital expenditures totaled $1.5M, while share buybacks reached $11.3M, contributing to a 5-year share count change of -4.7%.

Trading at a market capitalization of $99.4M and enterprise value of $97.9M, JYNT holds a trailing P/E of 50.2x, above the 24.6x median of its US-listed Healthcare peers. Its forward P/E of 11.9x sits below the peer group median of 17.3x, while its EV/EBITDA of 29.0x exceeds the peer median of 12.0x. JYNT trades at a price-to-sales multiple of 1.7x compared to the sector peer median of 4.1x. Over the past year, the stock declined 15.2% while the S&P 500 benchmark gained 16.8%. Over five years, the stock dropped 91.2% versus an 83.0% gain for the S&P 500.

Wall Street coverage includes 1 Strong Buy and 3 Hold recommendations. The mean price target of $10.00 suggests potential upside of 42.2% above the last close of $7.03. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $60.9M and EPS of $0.13, representing expected EPS growth of 750.0%. For the following fiscal year, 2 analysts project revenue of $62.6M and EPS of $0.67. The company beat EPS estimates in 3 of the last 4 quarters, with its next earnings report scheduled for November 5, 2026.

This page is an AI-written research summary of The Joint Corp. (JYNT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: JYNT income statement, JYNT balance sheet, JYNT key metrics, JYNT analyst forecast, JYNT chart. See the JYNT stock overview for the latest quote and news.